REGENTIS BIOMATERIALS LTD.
Business
Regentis Biomaterials Ltd. is a regenerative medicine company developing degradable hydrogel implants to regenerate damaged cartilage and bone tissue, primarily for orthopedic applications. Its main products include the Gelrin platform—notably GelrinC, an off‑the‑shelf, cell‑free hydrogel implant for knee articular cartilage repair—and pipeline candidates GelrinP and GelrinV. Key business activities encompass clinical development, regulatory submissions, intellectual property management and outsourced manufacturing via qualified CMOs. The company pursues commercialization through strategic partners, hospital and surgeon channels, and holds CE mark approval in Europe while conducting a pivotal trial in the United States and Europe.
Summary from filing dated 2026-02-24
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-13.65M |
| Total assets | $7.62M |
| Total liabilities | $2.87M |
| Stockholders' equity | $4.74M |
| Operating cash flow | $-1.38M |